March 25, 2010 | medio: Press Release
Disitertide (P144), jointly developed by ISDIN and Digna Biotech showed a statistically significant improvement versus placebo in the patients that perceived improvement of the treated skin area affected by systemic sclerosis
• After three months of treatment, 42,2% of the patients enrolled in the double blind placebo controlled proof of concept trial, recognized an improvement in the Disitertide treated area compared to the 17,8% of the patients that perceived improvement in the placebo treated area. The difference was statistically significant (p<0,034). • ISDIN and Digna Biotech have decided to continue the development of Disitertide for the systemic sclerosis treatment.